Clinical significance of microsatellite instability in sporadic epithelial ovarian tumors by 源��옱�슧 et al.
Yonsei Med J 49(2):272 - 278, 2008
DOI 10.3349/ymj.2008.49.2.272
Yonsei Med J Vol. 49, No. 2, 2008
Purpose: We evaluated the expression of microsatellite
instability (MSI) in sporadic ovarian tumors using 5 standard
and 9 new MSI markers to determine the clinical significance
of MSI in sporadic epithelial ovarian tumors. Materials and
Methods: MSI was examined in 21 borderline and 25 malignant
ovarian tumors. Polymerase chain reaction (PCR) was
performed using the 5 markers recommended by the National
Cancer Institute (NCI) for colon cancer and 9 additional
markers. MSI was determined using fractional analysis by
mixing the PCR products and size markers. Results: Using the
5 conventional MSI markers, MSI was found in 4 of 46 (8.6%)
ovarian tumors, including 2 of 21 (9.5%) borderline ovarian
tumors and 2 of 25 (8%) malignant ovarian tumors. Using the
9 additional MSI markers, MSI was observed in 7 of 46
(15.2%) ovarian tumors, including 3 of 21 (14.3%) borderline
ovarian tumors and 4 of 25 (16%) malignant ovarian tumors.
There was no statistically significant difference between MSI
and clinicopathological factors, including histology and stage,
although there was a trend toward an increased incidence of
MSI in the serous type. Conclusion: MSI was infrequent in
ovarian tumors, including both borderline and malignant
tumors. MSI was found to be uncommon in sporadic ovarian
tumors, even by using additional MSI markers. The clinical
significance of MSI is not strong in patients with sporadic
ovarian tumors.
Key Words: Microsatellite instability, polymerase chain
reaction, ovarian neoplasms
INTRODUCTION
Microsatellites are short tandem repeats of
DNA bases scattered throughout the genome, and
vary in size from tens to hundreds of bases. Micro-
satellite regions are at particular risk of mutation
such as the insertion or deletion of repeating units
during DNA replication; this change in length is
called MSI.1 In normal tissues, the mismatch
repair (MMR) system identifies and excises these
abnormalities that occur during DNA replication.
Therefore, a defect in the MMR system, including
the proteins hMLH1, hMLH3, hMSH2, hMSH3,
hMSH6, hPMS1, and hPMS2, results in MSI.2
Because defects in DNA mismatch repair are
related mainly to inherited mutations, MSI occurs
in about 90% of hereditary non-polyposis colorectal
cancer (HNPCC).
3
However, MSI has also been
observed in a variety of sporadic cancers, including
those of the colon, endometrium, pancreas, and
bladder.
4-7
The potential significance of MSI in
some tumors has been emphasized, and MSI has
been reported to play roles in tumor diagnosis,
prognosis, response to treatment, and tumor
biology.8
The incidence of MSI depends on which loci are
investigated, because of many microsatellite regions
within the human genome. To overcome this
confusion, the National Cancer Institute (NCI)
introduced guidelines defining MSI in colorectal
cancer.8 A panel of five microsatellite loci con-
sisting of two mononucleotide repeats (Bat25 and
Bat26) and three dinucleotide repeats (D2S123,
D5S346, and D17S250) was established. When
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these criteria were applied to ovarian carcinoma,
the reported frequency of high MSI was 11 -
14%.9,10 Using additional MSI markers, the
frequency of MSI in ovarian carcinoma varies
from 6 to 37%.10-15 Given these variable results, the
prevalence of MSI in ovarian tumors is not yet
clear. Therefore, we evaluated the occurrence of
MSI in 21 borderline and 25 malignant ovarian
tumors using both the five standard MSI markers
and nine new MSI markers and determined
clinical significance of MSI in sporadic epithelial
ovarian tumors.
MATERIALS AND METHODS
Patients and tissue samples
Paired tumor and normal samples were retrieved
from 46 patients with ovarian tumors who had
been treated surgically at the Department of
Obstetrics and Gynecology, Yonsei University
Medical Center in Korea. The tumor samples
included 21 borderline and 25 malignant ovarian
tumors. None of the patients had a personal or
family history of ovarian cancer or HNPCC
syndrome. The tumors were classified according
to the World Health Organization criteria and
staged using the International Federation of
Gynecology and Obstetrics (FIGO) staging system.
Of the 46 ovarian tumors, 10 were serous, 26
mucinous, and 10 endometrioid. Of the 25 malignant
ovarian tumors, 9, 3, and 13 were stages I, II, and
III, respectively.
DNA isolation and polymerase chain reaction
(PCR)
The tumor tissues were snap-frozen in liquid
nitrogen and stored at -70°C. Genomic DNA was
extracted from the frozen tumor tissues using a
DNA extraction kit according to the manufacturer’s
guidelines. To isolate normal DNA, paraffin-
embedded and formalin-fixed blocks were used.
Microdissection was performed on some sections
of the surgically resected gynecologic organs to
confirm the normal tissues. Normal DNA was
extracted from normal tissues using a kit
according to the manufacturer’s guidelines.
Tumor and normal DNA at 14 microsatellite
markers were amplified by PCR. The markers
used for the investigation included the National
Cancer Institute Consensus Panel (BAT25, BAT26,
D17S250, D2S123, and D5S346) and 9 other markers:
the dinucleotides NME1, D3S1611, D10S197, and
D11S904; the trinucleotide androgen receptor
(AR); and the tetranucleotides D13S175, DxS981,
DXS6800, and DXS6807. PCR was performed in a
total volume of 5 L, containing 0.5μ L of DNAμ
template, 0.475 L of each primer, and 2.5μ L ofμ
PCR MasterMix solution. PCR was carried out in
a thermal cycler, beginning with a 15-min dena-
turing step at 95°C, followed by 30 cycles of 94°C
for 45 s, 55°C for 45 s, and 72°C for 45 s, with a
final 10-min extension at 72°C.
Microsatellite analysis
After PCR, 0.5 L of each product was added toμ
0.5 L of GS500 size marker and 10μ L of Hi-Diμ
formamide. After 2 min at 95°C, the mixture was
immediately immersed in an ice bath. The am-
plified fragments were separated by denaturing
gel electrophoresis using an ABI PRISM 310
Genetic Analyzer (Applied Biosystems, Foster
City, CA). The data were analyzed using GeneScan
software (Applied Biosystems).
Microsatellite instability was defined as the
presence of extra or shifted bands in comparison
to the normal control. The tissues were classified
as high MSI (MSI-H) if instability was noted in
30% of the loci investigated, low MSI (MSI-L) if
instability was observed in < 30% of the loci
investigated, and stable tumors (MSS) if there was
no instability.
Statistical analysis
Chi-square test or Fisher’s exact test was used
to analyze the differences between parameters
using the program SPSS (version 12.0, Chicago, IL,
USA). A difference was considered significant at
p < 0.05.
RESULTS
DNA samples from 46 tumors and matched
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normal samples were analyzed for MSI (Fig. 1).
MSI was detected at the BAT25, BAT26, D2S123,
NME1, D13S175, and DXS981 loci.
Applying the NCI consensus definition of MSI
to the sporadic ovarian tumors, MSI was found in
4 of 46 (8.6%) ovarian tumors, including 2 of 21
(9.5%) borderline ovarian tumors (Table 1) and 2
of 25 (8%) malignant ovarian tumors (Table 2).
The MSI loci were BAT25 and BAT26. Whereas all
the borderline tumors with MSI were MSI-L
tumors, one of the two malignant ovarian tumors
with MSI was MSI-H.
When 9 more MSI markers were used to detect
MSI in sporadic ovarian tumors, MSI was seen in
7 of 46 (15.2%) ovarian tumors, including 3 of 21
(14.3%) borderline ovarian tumors (Table 1) and 4
of 25 (16%) malignant ovarian tumors (Table 2).
However, there was no MSI-H in any of these 7
cases.
To determine clinical significance of MSI in
sporadic ovarian tumors, we evaluated the
difference in MSI expression according to the
histological type and stage. MSI was found in 3
of 10 (30%) serous tumors, 3 of 26 (11%) mucinous
tumors, and 1 of 10 (10%) endometrioid tumors.
The incidence of MSI was higher in the serous
type, although the difference was not statistically
significant. According to the stage of malignant
ovarian tumors, MSI was observed in 1 of 9 (11%)
cases of stage I disease, none of 3 cases of stage
II, and 3 of 13 (23%) cases of stage III disease.
There was no significant difference in MSI
according to the stage of the malignant ovarian
tumor.
DISCUSSION
MSI is caused by mutations in the mismatch
repair genes. MSI has been implicated in the
pathogenesis of colon, endometrial, and gastric
carcinomas that occur in the setting of HNPCC
syndrome, and also in a subset of sporadic cancers
such as upper urinary tract, stomach, colon, and
endometrial carcinomas.16,17
In ovarian cancers, the reported incidence of
MSI ranges from 0 to 37%, depending on the
number and type of markers. Sood et al. first
reported the incidence of MSI in ovarian cancer
using the NCI criteria.9 Based on the NCI markers,
18% of tumors demonstrated MSI, of which 11%
were MSI-H and the remaining 7% were MSI-L. By
contrast, we found that only 4 of 46 (8.6%) ovarian
tumors had MSI. Similar to our results, Alvi et al.
observed MSI in 6.9% of sporadic ovarian cancer
by applying the NCI criteria,18 whereas Gras et al.
observed MSI in 3.8%,
19
suggesting that the NCI
standard-based MSI is infrequent in ovarian cancer.
When additional MSI markers such as mono-,
di-, and tetranucleotides were added to the
standard NCI markers, we found a slight increase
in the rate of MSI. Sood et al. also reported an
increase in the rate of MSI from 18% to 36% when
additional MSI markers were added.9 In other
cancer types, increased microsatellite changes at
selected tetranucleotides have been reported to be
important and are especially frequent in skin
(75%), head and neck (56%), lung (51%), and blad-
der (21 - 40%) cancers.20-23 However, the observed
increase of MSI with the additional MSI markers
Fig. 1. Example of microsatellite analysis comparing normal DNA and tumor DNA. A case shows microsatellite
instability (MSI) at BAT26.
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that we used was too weak to decide the
usefulness of the additional MSI markers. In
addition, the MSI-H observed by using the 5
standard MSI markers was downgraded to MSI-L
when all 14 MSI markers were used, suggesting
that additional MSI markers might not help detect
MSI in sporadic ovarian tumors.
To determine the clinical significance of MSI in
ovarian tumors, we evaluated the correlation
between MSI-positive tumors and some clinico-
pathological factors. There was no statistically
significant difference in the MSI rates according to
histological type or stage. The MSI rate was
higher in serous tumors than in endometrioid or
mucinous tumors, although it was not statistically
significant. Sood et al. also failed to find clinical
significance of MSI in ovarian cancers.9 On the
other hand, some investigators insist that MSI is
more prevalent in the endometrioid type because
ovarian endometrioid carcinoma is morpholo-
gically and biologically similar to the endometrial
endometrioid carcinoma and is the most prevalent
type of ovarian carcinoma in patients with
HNPCC.19 Nevertheless, Singer et al. suggested
that serous ovarian carcinoma had an intermediate
frequency of MSI,24 and Tangir et al. postulated
that MSI is an important pathogenic mechanism
in the development of serous tumors with low
malignant potential.13
The lack of MSI in this study could possibly be
due to the small number of samples. In addition,
the variation in the apparent MSI frequency might
have been due to the choice of microsatellites an-
alyzed, analytical methodology, tissue preservation
technique, and variable histology of ovarian cancer.
In conclusion, microsatellite instability was
infrequent in both borderline and malignant
ovarian tumors. Despite increasing the number of
MSI markers, MSI was found to be not common
in sporadic ovarian tumors. The clinical signi-
ficance of MSI appears to be weak in patients with
sporadic ovarian tumors. Therefore, further study
of molecular events that are correlated with
ovarian tumors is needed.
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